Overview

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Status:
Active, not recruiting

Trial end date:
2022-08-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of 48-week study intervention with JNJ-73763989+JNJ-56136379+nucleos(t)ide analog (NA) regimen compared to NA alone assessed by HBsAg levels. This study is part of HepB Wings Platform Trial (PLATFORMPAHPB2001).

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Sciences Ireland UC

Treatments:

Entecavir
Tenofovir